

GLAXOSMITHKLINE PLC  
Form 6-K  
October 31, 2008

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending October 31, 2008

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

**Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons**

I give below details of changes in the interests of Directors, Persons Discharging Managerial Responsibility or Connected Persons in the Ordinary shares of GlaxoSmithKline plc

in respect of the under

-

mentioned

persons

arising from the

grant of

options over

Ordinary shares

of 25

p each at a price of £9.51 per

share pursuant to

the GlaxoSmithKline UK Savings Related Share Option Plan

("the Plan") on 23 October 2008:

Mr S M Bicknell 1,009

Mr E J Gray 1,009

Mr A S Hussain 1,009

Mr D Learmouth 1,009

Mr D 1,009

S

Redfern

Mr A Witty 1,009

The Company

was

advised of

this information on

31 October

2008

.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a)

V A Whyte  
Deputy  
Company Secretary

31  
October

2008

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: October 31, 2008

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc